60 Degrees Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SXTP | PCSA | KPRX | ALGS | AVIR | ENTA | |
|---|---|---|---|---|---|---|
| Market cap | 3.36M | 5.41M | 7.34M | 31.35M | 357.71M | 310.19M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -0.5 | -0.7 | -1.0 | -3.0 | -4.5 |
| Price/book | -0.4 | -17.0 | 0.6 | 1.0 | 1.8 | 3.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −80.58% | −77.18% | −26.07% | −29.30% | +37.23% | −5.04% |
| Today | −5.32% | −0.26% | −4.05% | +5.68% | +6.95% | +2.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SXTP news ›60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmace... 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under…
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.(NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company fo... 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results WASHINGTON, Aug. 14, 2026…
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, ... 60 Degrees Pharmaceuticals…
Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Posted by Defense World Staff on Oct 17th, 2026 Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap healthcare companies, but which is the better stock?…
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Stock Short Interest Falls 38.3%
Posted by Mitch Edgeman on Oct 16th, 2026 Read Our Latest Research Report on SXTP 60 Degrees Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for infectious and…
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originall... 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP). In a report released today, Brendan Smith from TD Cowen maintained a…
60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study
60 Degrees Pharmaceuticals (SXTP) announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients h... 60 Degrees Pharmaceuticals to conclude enrollment in tafenoquine study 60 Degrees…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- defenseworld.net2
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.